Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Launched by ORION CORPORATION, ORION PHARMA · Sep 2, 2011
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Successful completion of study protocol 3104001
- • Response or stable disease in study 3104001 at week 12
- Exclusion Criteria:
- • New serious concurrent medical condition
- • Not able to swallow the study drug
About Orion Corporation, Orion Pharma
Orion Corporation, a Finnish pharmaceutical and biotechnology company, is dedicated to developing innovative healthcare solutions that enhance the quality of life for patients worldwide. With a strong focus on research and development, Orion Pharma specializes in prescription medications, particularly in the fields of neurology, oncology, and critical care. The company is committed to advancing medical science through rigorous clinical trials and collaborations, aiming to bring forth effective therapies that address unmet medical needs while adhering to the highest ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Tampere, , Finland
Cleveland, Ohio, United States
Myrtle Beach, South Carolina, United States
Cleveland, Ohio, United States
Villejuif, , France
Turku, , Finland
Oulu, , Finland
Manchester, , United Kingdom
Kuopio, , Finland
Birmingham, , United Kingdom
Oxford, , United Kingdom
Turku, , Finland
Cardiff, , United Kingdom
Paris, , France
Wheat Ridge, Colorado, United States
Norwich, Connecticut, United States
Hradec Králové, , Czech Republic
Tallinn, , Estonia
Patients applied
Trial Officials
Karim Fizazi
Principal Investigator
Gustave Roussy, Cancer Campus, Grand Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials